RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?

10.1080/07853890802698842

10.1016/S0092-8674(00)80620-0

10.1038/418244a

10.1038/35888

10.1038/mt.2011.263

10.2174/156802612798919141

10.1261/rna.037424.112

10.1089/nat.2012.0361

10.1038/mt.2013.55

10.1093/nar/gkt844

10.1124/dmd.113.055434

10.1021/ja505986a

10.1038/nmat3765

10.1126/scitranslmed.3008362

15. Arrowhead Res. Corp. 2015. ARC-AAT. http://www.arrowheadresearch.com/programs/arc-aat

10.1517/17425255.2014.922543

10.1186/1754-1611-6-7

10.4137/OED.S4878

19. Sylentis. 2013. Zeltia announces that subsidiary Sylentis has commenced Phase II clinical trials with its compound SYL1001 for treating eye discomfort associated with dry eye syndrome. News Release, Febr. 27.http://www.sylentis.com/index.php/en/healthcare-professional-news/54-zeltia-informa-que-su-filial-sylentis-inicia-la-fase-ii-de-ensayos-clinicos-con-su-compuesto-syl1001-para-el-tratamie-nto-del-dolor-ocular-asociado-al-sindrome-del-ojo-seco.html

10.1016/j.sjopt.2013.12.003

Gonzalez V, Investig. Ophthalmol. Vis. Sci., 53, 575 (Abstr.)

10.1038/mt.2013.216

23. Quark. 2015. PF-655. http://quarkpharma.com/?page_id=28

24. PR Newswire. 2011. In a Phase 2 Study PF-04523655(RTP801I-14)showed improved vision over standard of care in patients with diabetic macular edema at 12 months. News Release, Mar. 18.http://www.prnewswire.com/news-releases/in-a-phase-2-study-pf-04523655-rtp801i-14-showed-improved-vision-over-standard-of-care-in-patients-with-diabetic-macular-edema-at-12-months-118269674.html

25. Quark. 2015. QPI-1007. http://quarkpharma.com/?page_id=23

26. Quark. 2014. Quark announces first patient dosed in a Phase IIa trial evaluating QPI-1007 for neuroprotection in patients with acute primary angle closure glaucoma. News Release, June 25.http://globenewswire.com/news-release/2014/06/25/646585/10087108/en/Quark-Announces-First-Patient-Dosed-in-a-Phase-IIa-Trial-Evaluating-QPI-1007-for-Neuroprotection-in-Patients-With-Acute-Primary-Angle-Closure-Glaucoma.html

10.1016/S0140-6736(13)61914-5

28. Alnylam. 2015. Hemophilia. http://www.alnylam.com/product-pipeline/hemophilia/

29. Alnylam. 2015. Alnylam reports initial evidence for potential correction of the hemophilia phenotype in Phase 1 study of ALN-AT3, a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia. News Release, Jan. 11.http://investors.alnylam.com/releasedetail.cfm?ReleaseID=890625

10.1073/pnas.1406228111

31. Alnylam. 2015. Porphyria. http://www.alnylam.com/product-pipeline/porphyria/

32. Alnylam. 2015. Complement-mediated disease. http://www.alnylam.com/product-pipeline/complem-ent-mediated-disease/

33. Borodovsky A, Yuclus K, Sprague A, Banda NK, Holers VM, et al. 2014. ALN-CC5, an investigational RNAi therapeutic targeting C5 for complement inhibition. Proc. Am. Soc. Hematol., San Francisco, CA,2014. http://www.alnylam.com/web/assets/ALN-CC5_ASH_Dec2014_panel-by-panel.pdf

34. Alnylam. 2015. TTR amyloidosis(FAP). http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/

10.1056/NEJMoa1208760

36. Alnylam. 2014. Alnylam reports six-month clinical data from patisiran Phase 2 open-label extension(OLE)study in patients with familial amyloidotic polyneuropathy(FAP). News Release, Oct. 13.http://investors.alnylam.com/releasedetail.cfm?ReleaseID=875724

37. Alnylam. 2015. TTR amyloidosis(FAC). http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/

10.1038/mtna.2013.36

10.1039/b918869j

40. Nitto Denko. 2013. Leadership in fibrosis. http://www.ndtcorp.com/page/leadership-in-fibrosis

41. Nitto Denko. 2014. New anti-fibrosis drug with molecular targeting DDS completed Phase-1a dose escalation. News Release, Apr. 22.http://www.nitto.com/jp/en/press/2014/0422.jsp

10.1097/MEG.0000000000000010

43. Steinbach G, Courvalin P, Fruehauf J, Silva A. 2014. Phase I protocol: CEQ508 in FAP CEQ508.FAP.01. http://osp.od.nih.gov/sites/default/files/989_Steinbach_cln.pdf

44. Marina Biotech. 2015. Marina Biotech provides 2014 year-end financials and update. News Release, Febr. 25.http://www.marinabio.com/files/2414/2483/8505/15-02-25_-_Marina_Biotech_Provides_2014_Year-End_Financials_and_Update.pdf

10.1038/mt.2009.273

46. Pachyonychia Congenita Project. 2013. Clinical trials and studies. http://www.pachyonychia.org/clinical_trials_studies.php

47. RXi Pharmaceuticals. 2015. RXI-109.http://www.rxipharma.com/rxi-109/

48. RXi. 2014. RXi Pharmaceuticals announces sustained effect of RXI-109 at three months post scar revision surgery and the completion of enrollment for its Phase 2a trial RXI-109–1301. News Release, Dec. 17.http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-sustained-effect-of-rxi-109-at-three-months-post-scar-revision-surgery-and-the-completion-of-enrollment-for-its-phase-2a-trial-rxi-109-1301-300010991.html

49. Apeiron Biologics. 2014. APN401(Cbl-b). http://www.apeiron-biologics.com/index.php/projects/apn401-cbl-b.html

50. Salzberg MO, Lametschwandtner G, Schuster M, Loibner H, Sachet M, et al. 2014. Development of a personalized cellular ex-vivo CBL-b silencing cancer immune therapy. Proc. 2014 ASCO Annu. Meet.,Chicago, IL

51. Apeiron. 2015. Apeiron announces start of a Phase I trial with a unique cellular anti cancer therapy triggering immunological checkpoint blockade. News Release, Febr. 26.http://prd.at/en/newsroom-clients/apeiron-announces-start-of-a-phase-i-trial-with-a-unique-cellular-anti-cancer-therapy-triggering-immunological-checkpoint-blockade/

10.1159/000360993

53. Gradalis, Inc. 2013. FANG™ personalized tumor vaccine stimulates immune response and more than doubles time to recurrence in patients with advanced stage ovarian cancer. News Release, May 15.http://www.prnewswire.com/news-releases/fang-personalized-tumor-vaccine-stimulates-immune-response-and-more-than-doubles-time-to-recurrence-in-patients-with-advanced-stage-ovarian-cancer-207530021.html

10.18632/oncotarget.1825

55. Arbutus. 2015. TKM-PLK1. http://arbutusbio.com/portfolio/tkm-plk1.php

56. Arbutus. 2014. Tekmira provides update on TKM-PLK1 Phase I/II clinical study in patients with advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma. News Release, Dec. 31.http://globenewswire.com/news-release/2014/12/31/694562/10113745/en/Tekmira-Provides-Update-on-TKM-PLK1-Phase-I-II-Clinical-Study-in-Patients-With-Advanced-Gastrointes-tinal-Neuroendocrine-Tumors-and-Adrenocortical-Carcinoma.html

10.1038/cgt.2010.35

Gorovets D, 2014, J. Pancreas, 15, 95

10.1073/pnas.1314307110

Golan T, 2013, J. Clin. Oncol., 31, 4037 (Abstr.), 10.1200/jco.2013.31.15_suppl.4037

61. Silenseed. 2015. Pipeline: pancreatic cancer. http://silenseed.com/?page_id=2539

10.1158/0008-5472.CAN-05-0530

10.1158/1078-0432.CCR-12-2764

64. Macron D. 2013. MD Anderson team preps for Phase I testing of RNAi cancer drug. Genome Web. https://www.genomeweb.com/rnai/md-anderson-team-preps-phase-i-testing-rnai-cancer-drug

65. Dicerna. 2015. Dicerna Pharmaceuticals announces first patient dosed in Phase 1b/2 clinical trial of DCR-MYC, an investigational RNAi therapeutic targeting the MYC oncogene, in patients with advanced hepatocellular carcinoma. News Release, Febr. 2.http://investors.dicerna.com/releasedetail.cfm?releaseid=893991

66. Dicerna. 2014. DCR-MYC and the MYC oncogene. http://dicerna.com/pipeline/genetic-oncology/dcr-myc-and-the-myc-oncogene/

10.2174/1389450116666150213111603

68. Benitec Biopharma. 2015. In-house programs detail: 1. Hepatitis C. http://www.benitec.com/pipeline/in-house-programs-detail#hepc

10.4254/wjh.v7.i2.150

70. Arbutus. 2015. TKM-HBV. http://arbutusbio.com/portfolio/tkm-hbv.php

10.1038/mt.2013.31

72. Arrowhead Research. 2015. ARC-520. http://www.arrowheadresearch.com/programs/ARC-520

10.1111/j.1365-2893.2012.01602.x

74. Arrowhead Research. 2014. Arrowhead files IND for RNAi therapeutic ARC-520 to begin Phase 2b multiple-dose studies in chronic hepatitis B patients. News Release, Dec. 15.http://ir.arrowheadresearch.com/releasedetail.cfm?releaseid=887586

75. Arrowhead Research. 2015. Arrowhead provides update on IND for ARC-520 Phase 2b study. News Release, Jan. 12.http://ir.arrowheadresearch.com/releasedetail.cfm?releaseid=890676

76. Arrowhead Research. 2014. Arrowhead presents data on ARC-520 and ARC-AAT at AASLD The Liver Meeting® 2014. News Release, Nov. 10.http://ir.arrowheadresearch.com/releasedetail.cfm?releaseid=881791

10.1016/S0140-6736(10)60357-1

78. Haussecker D. 2014. Developing aerosolized TKM-EBOLA as airborne transmission of Ebola likely.

79. Arbutus. 2015. Tekmira initiates Phase I clinical trial of TKM-HBV. News Release, Jan. 21.http://www.sec.gov/Archives/edgar/data/1447028/000117184315000285/newsrelease.htm

80. Dicerna. 2015. EMA grants orphan drug designation to DCR-PH1, Dicerna's investigational therapy for the treatment of primary hyperoxaluria type 1(PH1). News Release, Aug. 6.http://www.businesswire.com/news/home/20150806006411/en/EMA-Grants-Orphan-Drug-Designation-DCR-PH1-Dicernas#.VgWExN9VhBc

81. Alnylam. 2015. Alnylam files clinical trial application(CTA)for ALN-AAT, an investigational RNAi therapeutic for the treatment of alpha-1 antitrypsin deficiency-associated liver disease(alpha-1 liver disease). News Release, May 17.http://investors.alnylam.com/releasedetail.cfm?ReleaseID=913507

82. Arbutus. 2015. Tekmira provides corporate update and announces year-end 2014 results. News Release, Mar. 12.http://investor.arbutusbio.com/releasedetail.cfm?ReleaseID=901392

10.1038/nature14442

84. Arbutus. 2015. TKM-Ebola-Guinea enters Phase II clinical study in Sierra Leone. News Release, Mar. 11.http://investor.arbutusbio.com/releasedetail.cfm?ReleaseID=901104